期刊文献+

磁共振ASL技术在鉴别高级别脑胶质瘤治疗后假性进展中的应用 被引量:6

Application of MRI ASL in Identifying Pseudothe Science, Technology & Innovation Commission of Shenzhen Municipality-progression of High Grade Glioma after Treatment
下载PDF
导出
摘要 目的探讨MRI动脉自旋标记(ASL)技术对高级别胶质瘤术后放化疗患者假性进展与复发的诊断价值。方法应用3.0TMR对32例术后和放化疗后的随访MR中发现新的异常强化灶的高级别胶质瘤患者进行2DpASL检查。患者基于随后的病理分析或临床放射学随访被分为假性进展组(n=7)和胶质瘤复发组(n=25)。使用Wilcocon秩和检验比较两组之间的损伤灌注参数值rCBF。ROC曲线评估rCBF在复发假性进展中的诊断性能。结果对比增强病变中,假性进展组的rCBF显着低于胶质瘤复发组((1.45±0.25)对(3.16±0.14)Z=-3.739,P=0.000)rCBF在假性进展诊断中ROC曲线下面积为0.765(95%置信区间:0.597-0.932),灵敏度为0.647,特异性为0.733。结论 ASL有助于区分治疗后常规随访MRI的新发展增强病变的高级别胶质瘤患者的假性进展和复发。 Objective To investigate the diagnosis performance of arterialspin labeling(ASL in distinguishing pseudoprogression from recurrence in postoperation chemoradiotherapy patients with high-grade glioma.Methods 2 D pASL was performed using a 3.0 Tesla scanner in 32 patients with high-grade glioma,who received previously resection and chemoradiotherapy,and newly developed abnormal contrast-enhanced lesions were noted at rountine following-up MRI.These patients were classified into a pseudoprogression group(n=7)and glioma recurrence group(n=25)based on subsequent pathologic analysis or clinical–radiological follow-up.Lesion perfusion parameter values-rCBF was compared between the two groups using Wilcocon rank sum test.The diagnosis performance of rCBF in distiguishing pseudoprogression from recurrence were assessed receiptor operation characteristic(ROC)curve.Results For the contrast-enhanced lesions,the rCBF in the pseudoprogression group was significantly lower than that in the glioma recurrence group((1.45±0.25)vs(3.16±0.14)Z=-3.739,P=0.000)The area under the ROC curve was 0.765(95%confidence interval:0.597-0.932)with a sensitivity of 0.647 and a specificity of 0.733 for rCBF in diagnosis of pseudoprogression.Conclusion ASL is helpful in differentiating pseudoprogression from recurrence in high grade giloma patients with newly development enhanced lesions during routine following-up MRI after therapy.
作者 胡丽霞 朱进 唐娜 周略 李子煌 龚静山 李先明 HU Li-xia;ZHU Jin;TANG Na(Department of Imaging Diagnostic,Jinan University Second Clinical Medical College(Shenzhen People's Hospital),Shenzhen 518020,Guangdong Province,China;不详)
出处 《中国CT和MRI杂志》 2019年第8期4-7,35,共5页 Chinese Journal of CT and MRI
基金 深圳市科创委基金项目,项目编号:JCYJ20180305180540801
关键词 核磁共振 脉冲式标记 相对脑血流量(rCBF)值 假性进展 胶质瘤复发 MRI pASL rCBF Pseudo-progression Glioma Recurrence
  • 相关文献

参考文献2

二级参考文献25

  • 1Louis DN, Ohgaki H, Wiestler OD, et al. WHO classification of turnouts of the central nervous system [ J ]. Acta Neuropathol, 2007, 114(2) : 97-109.
  • 2Kim HS, Kim SY. A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas [ J ]. American Journal of Neuroradiology, 2007, 28(9) : 1693-1699.
  • 3Hoffman WF, Levin VA, Wilson CB, et al. Evaluation of malig- nant glioma patients during the postirradiation period [ J ]. Jour- nal of neurosurgery, 1979, 50 (5) :624-628.
  • 4deWit MC, de Brain HG, Eijkenboom W, et al. Immediate postra- diotherapy changes in malignant glioma can mimic tumor progres- sion [J]. Neurology, 2004, 63(3):535-537.
  • 5Brandsma D, Stalpers L, Taal W, et al. Clinical features, mech- anismsand management of pseudoprogression in malignant glioma [J]. Lancet Oneol, 2008, 9(5): 453-461.
  • 6Van Mieghem E, Wozniak A, Geussens Y, et al. Defining pseu- doprogression in glioblastomamuhiforme [ J 1. Eur J Neurol, 2013, 20(10) : 1335-1341.
  • 7Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [ J]. N Engl J Med, 2005, 352(10) : 987-996.
  • 8Oborski MJ, Laymon CM, Lieberman FS, et al. Distingnishingp- seudoprogression from progression in high-grade gliomas: a brief review of current clinical practice and demonstration of the poten- tial value of ^18F-FDG PET [ J ]. Journal of Nuclear Materials, 2013, 38(5) : 381-384.
  • 9Mangla R, Ginat DT, Kamalian S, et al. Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade Ⅲ glioma subtypes [ J]. Journalof Neu- ro-Oncology, 2014, 116(2) : 325-331.
  • 10Algizawiy M, Prah M, Mueller W, et al. DSC-MRI measures of rCBV predict tumor characteristics beyond stardard histopathology [Jl. Neuro-Oncology, 2014, 16(5) : 138-158.

共引文献22

同被引文献44

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部